Listed by the USPTO as FONTAINHAS, AURORA M
Tech Center 1600 • Art Units: 1649 1674 1675
This examiner grants 38% of resolved cases
FONTAINHAS, AURORA M has resolved 498 cases in tech center 1600 and art unit 1649. The allowance rate is 37.8%, while the median time to allowance is 1195 days. The profile shows a lower allowance outcome alongside a prolonged prosecution path, making careful initial claim drafting and response sequencing relevant to applicants.
Interviews are associated with a 49.4% lift in allowance outcomes. Novartis AG, Boehringer Ingelheim International GmbH, and Merck Patent GmbH are the leading companies listed. ALSTON & BIRD LLP, BALLARD SPAHR LLP, and BENESCH, FRIEDLANDER, COPLAN & ARONOFF LLP are the leading firms shown. The interview figure supports deliberate preparation for examiner discussions.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18423352 | ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES | Non-Final OA | Boehringer Ingelheim International GmbH |
| 17932796 | Cladribine regimen for treating progressive forms of Multiple Sclerosis | Non-Final OA | Merck Patent GmbH |
| 17914817 | Uses of Tau Phosphosites as Biomarkers for Alzheimer's Disease | Final Rejection | Washington University |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy37.8% of resolved applications examined by Aurora M Fontainhas were allowed (498 resolved cases), compared with 26.3% across Art Unit 1649 over the last five years.
This examiner's interview lift is +49.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Aurora M Fontainhas took 1,195 days on average from filing to allowance.
Aurora M Fontainhas examines applications in Art Unit 1649 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
